Trends in Participation Rates of the National Cancer Screening Program among Cancer Survivors in Korea

Yun, E Hwa; Hong, Seri; Her, Eun Young; Park, Sohee; Choi, Kui Son; Jun, Jae Kwan

doi:10.3390/cancers13010081

Cited by 12 publications

(9 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, a study that evaluated the trend of cancer survivors in the Korean National Cancer Screening Program found the screening rate among cancer survivors over 10 years (2022-2014) to be increasing (stomach cancer, 50.3%; breast cancer, 49.7%; cervical cancer, 45.2%; and colorectal cancer, 28.0%). [40] These rates were still low, so SPC screening education and encouragement should be emphasized along with healthy behaviors. In this study, the SPC screening rates among controls and BCSs were 73.2% and 74.8%, respectively.…”

Section: Discussionmentioning

confidence: 99%

Health-promoting behaviors among middle-aged breast cancer survivors compared with matched non-cancer controls: A KNHANES VI-VII (2013–2018) study

Jeong

Choe

2023

Medicine

View full text Add to dashboard Cite

This study aimed to compare health-promoting behaviors between middle-aged breast cancer survivors and matched non-cancer controls. We conducted a retrospective, cross-sectional, matched case-control study using data from Korean National Health and Nutrition Examination Surveys (KNHANES) VI-VII (2013–2018) to compare health-promoting behaviors. We selected breast cancer survivors aged 40 to 65 who completed the surveys, and each case was matched with 5 non-cancer controls (1:5) based on propensity scores. With multivariable logistic regression, middle-aged breast cancer survivors were compared with controls in terms of their last screening for a second primary cancer (SPC), current smoking status, alcohol consumption, aerobic physical activity (PA), sedentary time, and self-reported diet control. The final study sample consisted of 117 middle-aged breast cancer survivors and 585 non-cancer controls after propensity score matching (PSM). In the multivariable analysis, middle-aged breast cancer survivors were less likely to consume alcohol (odds ratio [OR] 0.58, 95% confidence interval [CI], 0.35–0.95), more likely to engage in aerobic PA (OR, 1.60; 95% CI, 1.01–2.54), and more likely to self-report diet control (OR, 2.12; 95% CI, 1.27–3.53). There were no significant intergroup differences in SPC screening uptake within 2 years, smoking status, or sedentary times. There is a need to educate middle-aged breast cancer survivors about SPC screening, smoking cessation, and minimizing sedentariness to reduce the risks of associated with breast cancer recurrence, SPCs, and comorbid chronic diseases.

show abstract

Section: Discussionmentioning

confidence: 99%

Health-promoting behaviors among middle-aged breast cancer survivors compared with matched non-cancer controls: A KNHANES VI-VII (2013–2018) study

Jeong

Choe

2023

Medicine

View full text Add to dashboard Cite

show abstract

“…According to the National Cancer Screening Program (NCSP) in South Korea and our transplant program protocol, all transplant candidates undergo cancer screening [ 18 ]. We perform esophagogastroduodenoscopy (for patients aged ≥16 years), colonoscopy (for patients aged ≥40 years), and abdominal ultrasonography (USG).…”

Section: Methodsmentioning

confidence: 99%

Hepatocellular carcinoma and cancer-related mortality after kidney transplantation with rituximab treatment

et al. 2022

View full text Add to dashboard Cite

Purpose There are increased therapeutic usages of rituximab in kidney transplantation (KT). However, few studies have evaluated the effect of rituximab on cancer development following KT. This study aimed to evaluate the effect of rituximab on the cancer occurrence and mortality rate according to each type of cancer. Methods Five thousand consecutive recipients who underwent KT at our center were divided into era1 (1990–2007) and era2-rit– (2008–2018), and era2-rit+ (2008–2018) groups. The era2-rit+ group included patients who received single-dose rituximab (200–500 mg) as a desensitization treatment 1–2 weeks before KT. Results The 5-year incidence rates of malignant tumors after KT were 3.1%, 4.3%, and 3.5% in the era1, era2-rit–, and era2-rit+ group, respectively. The overall incidence rate of cancer after transplantation among the 3 study groups showed no significant difference (P = 0.340). The overall cancer-related mortality rate was 17.1% (53 of 310). Hepatocellular carcinoma (HCC) had the highest mortality rate (61.5%) and relative risk of cancer-related death (hazard ratio, 8.29; 95% confidence interval, 2.40–28.69; P = 0.001). However, we found no significant association between rituximab and the incidence of any malignancy. Conclusion Our results suggest that single-dose rituximab for desensitization may not increase the risk of malignant disease or cancer-related mortality in KT recipients. HCC was associated with the highest risk of cancer-related mortality in an endemic area of HBV infection.

show abstract

“…A study on the trends in socioeconomic inequalities in cancer screening services in Korea reported that inequalities and inequities in participation in gastric and colorectal cancer screening were weakened after the implementation of the NCSP, however, reducing only out-of-pocket expenses for cancer screening may not completely eliminate the inequality [36]. Previous studies have identified health system-related characteristics as the cause of non-participation [37]. Another study reported that barriers to cancer screening included lack of time, lack of knowledge about cancer screening programs, physical disability or underlying disease, and logistic barriers [38].…”

Section: E P U B a H E A D O F P R I N Tmentioning

confidence: 99%

The impact of COVID-19 on screening for colorectal, gastric, breast, and cervical cancer in Korea

et al. 2022

View full text Add to dashboard Cite

Objectives:The COVID-19 pandemic has affected the utilization of healthcare services, such as participation in cancer screening programs. We compared cancer screening participation rates for colorectal, gastric, breast, and cervical cancers among participants in the National Cancer Screening Program (NCSP) in 2019 and 2020 to address the potential distraction effect of COVID-19 on cancer screening.Methods: Data from the NCSP for four cancer types (stomach, colorectal, breast and cervical) in 2019 and 2020 were used to calculate cancer screening participation rates by calendar month, gender, age group, and geographical region. Monthly participation rates were analyzed per 1,000 eligible individuals. Results:The screening participation rate decreased in 2020 compared to 2019 for all four cancers: colorectal (40.5% vs. 35.3%), gastric (61.9% vs. 54.6%), breast (63.8% vs. 55.8%), and cervical cancers (57.8% vs. 52.2%). Following two major COVID-19 waves in March and December 2020, the participation rates in the four types of cancer screening dropped compared with those in 2019. The highest decline was observed in the elderly population aged 80 years and older (percentage change: -21% for colorectal cancer; -20% for gastric cancer; -26% for breast cancer; -20% for cervical cancer). Conclusions:After the two major COVID-19 waves, the screening participation rate for the four types of cancer declined compared with 2019. Further studies are needed to identify the indirect effects of the COVID-19 pandemic on cancer patients, such as delayed diagnosis of cancer or excess cancer deaths.

show abstract

Trends in Participation Rates of the National Cancer Screening Program among Cancer Survivors in Korea

Cited by 12 publications

References 30 publications

Health-promoting behaviors among middle-aged breast cancer survivors compared with matched non-cancer controls: A KNHANES VI-VII (2013–2018) study

Health-promoting behaviors among middle-aged breast cancer survivors compared with matched non-cancer controls: A KNHANES VI-VII (2013–2018) study

Hepatocellular carcinoma and cancer-related mortality after kidney transplantation with rituximab treatment

The impact of COVID-19 on screening for colorectal, gastric, breast, and cervical cancer in Korea

Contact Info

Product

Resources

About